<DOC>
	<DOC>NCT01160289</DOC>
	<brief_summary>The primary purpose of the study is to compare the efficacy of LY2452473 + tadalafil to tadalafil alone in improving the erectile function (EF) of men with erectile dysfunction (ED) who incompletely respond to tadalafil alone.</brief_summary>
	<brief_title>A Study of LY900010 in Erectile Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Inclusion Criteria include: Ambulatory men History of Erectile Dysfunction of at least 3 months duration History of incomplete response to any phosphodiesterase type 5 inhibitor (PDE5i) at the maximum tolerated dose within the label Anticipate having the same female sexual partner throughout the duration of the study Are willing and able to make at least 4 sexual intercourse attempts with the female sexual partner during each 4week segment of the study Agree to use birth control during the study and for 60 days after the study, unless the female partner is postmenopausal Agree not to use any other Erectile Dysfunction treatment, including herbal treatment, during the study and for 96 hours after the last dose of study drug Screening laboratory tests within normal limits except for testosterone Without a language barrier, are reliable and willing to follow study procedures ProstateSpecific Antigen (PSA) less than 10 ng/ml. Men with PSA greater than 4 and less than 10 ng/ml must have documentation of a negative histological biopsy of carcinoma of prostate within 12 months prior to screening Exclusion Criteria include: History of penile implant History of no response to injection therapy for Erectile Dysfunction History of radical prostatectomy or other pelvic surgery with subsequent failure to achieve any erection Exhibit the presence of clinically significant penile deformity in the opinion of the investigator History of prior sexual legal convictions Bilateral hip replacements History of cancer within the previous 5 years, except for excised superficial lesions such as basal cell carcinoma and squamous cell carcinoma of the skin Chronic stable angina currently treated with longacting nitrates Chronic stable angina requiring treatment with shortacting nitrates within 90 days prior to screening Angina occurring during sexual intercourse in the 6 months prior to screening Unstable angina within 6 months prior to screening Myocardial infarction or coronary artery bypass graft surgery within 90 days prior to screening Angioplasty or stent placement within 90 days prior to screening Congestive heart failure within 6 months prior to screening History of sudden cardiac arrest Supraventricular arrythmia with an uncontrolled ventricular response at rest, or any history of spontaneous or induced sustained ventricular tachycardia, or use an automatic internal cardioverterdefibrillator An abnormality in the 12lead ECG that in the opinion of the investigator places the subject in an unacceptable risk for study participation Systolic blood pressure greater than 170 or less than 90 mm Hg or diastolic blood pressure greater than 100 or less than 50 mm Hg at screening Hepatic, renal, HIV, or clinically significant active neuropsychiatric disease History of central nervous system injuries (including stroke or spinal cord injury) within 6 months prior to screening Alcohol intake of 5 units or greater per day (1 unit = 12 ounces beer, 5 ounces wine, or 1.5 ounces of 80proof distilled spirits Receiving treatment with antiandrogens or 5alpha reductase inhibitor Anabolic steroids, calcitonin, oral bisphosphonates, Vitamin D greater than 50,000 IU/week, DHEA, steroidal supplements, nutritional products intended to have weight reduction or performance enhancing effects, herbal supplements within 7 days prior to screening Currently treated with a potent cytochrome P450 (CYP) 3A4 inhibitor, such as systemic ketoconazole or ritonavir, or a CYP3A4 inducer such as rifampicin</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>